Journal Review: Andrew Blauvelt

February 15, 2023

Andrew Blauvelt, MD, MBA, a dermatologist at the Oregon Medical Research Center in Portland, Oregon, reviews the effect of ruxolitinib cream on itch in patients with atopic dermatitis, including the mechanism of action of this effect, along with two recent studies published in the Journal of the American Academy of Dermatology¹ and Journal of the European Academy of Dermatology and Venereology² that have investigated improvements in itch with ruxolitinib.

References

1. Blauvelt A, Szepietowski JC, Papp K, et al. Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studies. J Am Acad Dermatol. 2022 Sep 14;S0190-9622(22)02688-3.

2. Blauvelt A, Kircik L, 2, Papp KA, et al. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):137–146.

MORE JOURNAL REVIEWS

Emmy Graber, MD, MBA: Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel plus Clascoterone 1% Cream in Adult Patients with Acne

Dr. Graber discusses her article published in JCAD January 2025, titled “Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl...

Naiem T. Issa, MD, PhD: Real-World Use of Tapinarof Cream 1% Once Daily in Patients with Seborrheic Dermatitis: A Case Series

Dr. Naiem T. Issa presents a case series on the real-world application of Tapinarof Cream 1% once daily in patients with seborrheic dermatitis, highlighting its...

Nada Elbuluk, MD, MSc: Utilization of Internet and Social Media by Outpatient Dermatology Patients: A Prospective, Cross-sectional Study

Dr. Nada Elbuluk presents findings on how outpatient dermatology patients use the internet and social media to acquire dermatology-related information. Topics Covered: Patient behavior in...

Tina Bhutani, MD: Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis

Dr. Tina Bhutani reviews real-world data showing improved patient-reported outcomes and satisfaction with tildrakizumab in moderate-to-severe plaque psoriasis. Topics Covered: Tildrakizumab 100mg over 64 weeks...

Alice Gottlieb, MD, PhD: Diagnostic Delay of Psoriatic Arthritis of More Than Six Months Contributes to Poor Patient-Reported Outcome Measures in Depression, Social Ability, and Disease Impact

Alice Gottlieb, MD, PhD, discusses a new article published in the October 2024 issue of JCAD that sought to correlate the time lag between psoriatic...

James Del Rosso, DO: Clindamycin— A Comprehensive Status Report with Emphasis on Use in Dermatology

James Del Rosso, DO, Clinical Editor-in-Chief of JCAD, discusses a new review article published in the August 2024 issue of JCAD, titled “Clindamycin: A Comprehensive...

Emmy Graber, MD, MBA: Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel plus Clascoterone 1% Cream in Adult Patients with Acne

Dr. Graber discusses her article published in JCAD January 2025, titled “Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl

Naiem T. Issa, MD, PhD: Real-World Use of Tapinarof Cream 1% Once Daily in Patients with Seborrheic Dermatitis: A Case Series

Dr. Naiem T. Issa presents a case series on the real-world application of Tapinarof Cream 1% once daily in patients with seborrheic dermatitis, highlighting its

Nada Elbuluk, MD, MSc: Utilization of Internet and Social Media by Outpatient Dermatology Patients: A Prospective, Cross-sectional Study

Dr. Nada Elbuluk presents findings on how outpatient dermatology patients use the internet and social media to acquire dermatology-related information. Topics Covered: Patient behavior in

Tina Bhutani, MD: Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis

Dr. Tina Bhutani reviews real-world data showing improved patient-reported outcomes and satisfaction with tildrakizumab in moderate-to-severe plaque psoriasis. Topics Covered: Tildrakizumab 100mg over 64 weeks

Alice Gottlieb, MD, PhD: Diagnostic Delay of Psoriatic Arthritis of More Than Six Months Contributes to Poor Patient-Reported Outcome Measures in Depression, Social Ability, and Disease Impact

Alice Gottlieb, MD, PhD, discusses a new article published in the October 2024 issue of JCAD that sought to correlate the time lag between psoriatic

James Del Rosso, DO: Clindamycin— A Comprehensive Status Report with Emphasis on Use in Dermatology

James Del Rosso, DO, Clinical Editor-in-Chief of JCAD, discusses a new review article published in the August 2024 issue of JCAD, titled “Clindamycin: A Comprehensive

Journal Review: Linda Stein Gold

Linda Stein Gold, MD, discusses an article published in the Journal of Drugs in Dermatology titled, "Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe

Journal Review: Valerie Callender

Valerie Callender, MD, is the Founder and Medical Director of the Callender Dermatology & Cosmetic Center, and is known for her sensitive and cutting-edge approach

Journal Review: Nanette Silverberg (Full Manuscript)

Nanette Silverberg, MD, a Clinical Professor of Pediatrics and Dermatology at the Icahn School of Medicine at Mount Sinai in New York, New York, provides

Journal Review: Sabrina Fabi

Sabrina Fabi, MD, discusses the article, “Customized Treatment Using Microfocused Ultrasound with Visualization for OptimizedPatient Outcomes: A Review of Skin-tightening Energy Technologies and a Pan-Asian

JCAD

Journal of Clinical and Aesthetic Dermatology

©2025 JCAD | The Journal of Clinical and Aesthetic Dermatology. All Rights Reserved.